Moderna Inc. — Sponsor Intelligence | 12 EU Trials

Filter these 12 trials by condition, phase, country and more.

Open in Search →

12 Registered trials

3 Recruiting

8 Completed trials

12 Countries active

34 Unique IMPs

100% Results reported

Phase III

Phase I (FiH)

Phase III: 2 Phase II: 1 Phase I/II: 1 Phase IV: 1 Phase I (Other): 1 Phase I (FiH): 6

Oversight events:

1 serious breach 16 temporary halts 1 urgent safety measure 2 unexpected events across 5 trials

View oversight register →

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cytomegalovirus immunisation 1 Non-small cell lung cancer metastatic 1 Methylmalonic aciduria 1 Influenza 1 Glycogen storage disease type I 1

Top IMPs

MODIFIED MESSENGER RIBONUCLEIC ACID ENCODING HUMAN PROPIONYL-COENZYME A CARBOXYLASE ALPHA AND BETA SUBUNITS ENCAPSULATED INTO LIPID NANOPARTICLES 2 MODIFIED MRNA ENCODING HUMAN METHYLMALONYL-COENZYME A MUTASE CONTAINING A POLYMORPHISM AT POSITION 671 2 MRNA-1345 2 SODIUM CHLORIDE 2 B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B/AUSTRIA/1359417/2021-LIKE STRAIN (B/AUSTRIA/1359417/2021, BVR-26), A/VICTORIA/4897/2022 (H1N1)PDM09-LIKE STRAIN (A/VICTORIA/4897/2022, IVR-238), INFLUENZA VIRUS A/THAILAND/8/2022 (H3N2) IVR-237-LIKE STRAIN (A/THAILAND/8/2022) 1 CX-039776, CX-044933, CX-037231 1 ELASOMERAN 1 IPILIMUMAB 1 MRNA ENCODING HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B, MRNA ENCODING HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN H, MRNA ENCODING HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN L, MRNA ENCODING HUMAN CYTOMEGALOVIRUS UL128, MRNA ENCODING HUMAN CYTOMEGALOVIRUS UL130, MRNA ENCODING HUMAN CYTOMEGALOVIRUS UL131A 1 MRNA ENCODING HUMAN GLUCOSE-6-PHOSPHATASE VARIANT S298C 1 MRNA-1365-RSV 1 MRNA-3210 1

All trials

12 total

A study to learn how mRNA 4359 works in the body and how safe it is in participants with advanced solid tumor cancer when administered alone… Recruiting

2023-504506-11-00 Phase I (FiH) 4 countries IPILIMUMAB; MRNA-4359; NIVOLUMAB
A study to assess the long-term safety and clinical activity of mRNA-3927 in participants previously enrolled in the mRNA-3927-P101 study Recruiting

2022-502911-12-00 Phase I/II 3 countries MODIFIED MESSENGER RIBONUCLEIC ACID ENCODING HUMAN PROPIONYL-COENZYME A CARBOXYL…
Phase 1/2 study of mRNA-3705 in participants with Isolated MMA (Extension Study). Recruiting

2022-501997-20-00 Phase I (FiH) 3 countries MODIFIED MRNA ENCODING HUMAN METHYLMALONYL-COENZYME A MUTASE CONTAINING A POLYMO…
A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness and Safety of mRNA-1273 Variant-Containing Vaccine Formulation Against S… Ended

2025-523841-82-00 Phase IV 1 country ELASOMERAN
A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Halted

2022-502910-10-00 Phase I (FiH) 4 countries MODIFIED MESSENGER RIBONUCLEIC ACID ENCODING HUMAN PROPIONYL-COENZYME A CARBOXYL…
A Study to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Influenza Vaccine Compared with a Licensed Influenza … Ended

2024-516240-26-00 Phase III 5 countries B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), INFLUENZA VIRUS B…
A study to investigate the reactogenicity, safety, and immunogenicity of mRNA-1345 in pregnant women, and safety and immunogenicity in their… Ended

2023-505359-37-00 Phase II 1 country MRNA-1345
A Phase 1/2, adaptive, open-label, single ascending dose to multiple ascending dose study to evaluate the safety, tolerability, pharmacokine… Ended

2022-502963-39-00 Phase I (FiH) 4 countries MRNA ENCODING HUMAN GLUCOSE-6-PHOSPHATASE VARIANT S298C; SODIUM CHLORIDE
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months Ended

2022-502022-41-00 Phase I (Other) 3 countries MRNA-1345; MRNA-1365-RSV; N. MENINGITIDIS GROUP C (STRAIN C11) POLYSACCHARIDE (D…
A clinical study to evaluate mRNA-3705 in Patients with MMA Ended

2022-502492-32-00 Phase I (FiH) 3 countries MODIFIED MRNA ENCODING HUMAN METHYLMALONYL-COENZYME A MUTASE CONTAINING A POLYMO…
Evaluating the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Ended

2023-508820-37-00 Phase III 7 countries MRNA ENCODING HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B, MRNA ENCODING HUMAN CYTOMEGA…
A dose-finding study to evaluate mRNA-3210 in participants with phenylketonuria Ended

2023-506963-32-00 Phase I (FiH) 3 countries MRNA-3210

Showing 1–12 of 12 trials

← All sponsors A–Z